Scholar Rock Holding Corporation (NASDAQ:SRRK): FDA Approval and Citigroup Upgrade Boost Biopharma Stock Outlook

• Scholar Rock Holding Corporation secured U.S. FDA approval for ISEMBYLD, a novel treatment for spinal muscular atrophy (SMA).
• Following this key development, Citigroup reaffirmed its "Buy" rating and increased its price target for the biopharmaceutical stock to $74.00.
• The company demonstrates strong market presence with a market capitalization of approximately $6.64 billion and active trading.

Scholar Rock Holding Corporation (NASDAQ:SRRK) is a leading biopharmaceutical company dedicated to drug development for serious diseases. The company recently presented at Citigroup's Biopharma Back to School Summit 2026, as highlighted by Seeking Alpha. These industry events allow companies to provide key updates to the investment community, which can significantly influence analyst ratings and investor decisions.

A significant development for Scholar Rock is the recent U.S. Food and Drug Administration (FDA) approval for its innovative drug, ISEMBYLD. As reported by Business Wire, this marks a milestone as the first muscle-targeted treatment for spinal muscular atrophy (SMA). The drug is approved for use in children and adults who are already receiving other treatments for the condition, underscoring its potential impact on patient care.

Following this crucial FDA approval, Citigroup maintained its "Buy" rating on Scholar Rock on September 14, 2026. The firm also raised its stock price target on the biopharmaceutical stock to $74.00 from $60.00. A price target is an analyst's projection of a stock's future price, and an increase often signals a positive investment outlook for the company.

At the time of the analyst action, Scholar Rock’s stock price was $55.41. Over the past 52 weeks, the stock performance has shown significant movement, trading between a low of $27.07 and a high of $61.76. The daily trading volume was over 994,000 shares, indicating active investor interest and liquidity in the market.

The company currently boasts a robust market capitalization of approximately $6.64 billion. Market capitalization represents the total value of all a company's outstanding shares of stock. It is calculated by multiplying the current stock price by its total number of outstanding shares, providing a key metric for understanding the company's size and overall company valuation from the market's perspective.